{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:31:35Z","timestamp":1760189495159},"reference-count":105,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ackdjournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1053\/j.ackd.2015.12.004","type":"journal-article","created":{"date-parts":[[2016,6,18]],"date-time":"2016-06-18T14:31:00Z","timestamp":1466260260000},"page":"247-254","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Treatment of Hyperlipidemia Changes With Level of Kidney Function\u2014Rationale"],"prefix":"10.1053","volume":"23","author":[{"given":"Shubha","family":"Ananthakrishnan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George A.","family":"Kaysen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.ackd.2015.12.004_bib1","series-title":"USRDS 17th Annual Report","first-page":"128","year":"2005"},{"issue":"13","key":"10.1053\/j.ackd.2015.12.004_bib2","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J\u00a0Med"},{"issue":"18","key":"10.1053\/j.ackd.2015.12.004_bib3","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","article-title":"Prediction of coronary heart disease using risk factor categories","volume":"97","author":"Wilson","year":"1998","journal-title":"Circulation"},{"issue":"5","key":"10.1053\/j.ackd.2015.12.004_bib4","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1046\/j.1523-1755.2002.00324.x","article-title":"Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients","volume":"61","author":"Iseki","year":"2002","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ackd.2015.12.004_bib5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1681\/ASN.2006070795","article-title":"Association between serum lipids and survival in hemodialysis patients and impact of race","volume":"18","author":"Kilpatrick","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ackd.2015.12.004_bib6","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000083529","article-title":"Low-density lipoprotein cholesterol: association with mortality and hospitalization in hemodialysis patients","volume":"23","author":"Chiang","year":"2005","journal-title":"Blood Purif"},{"issue":"24","key":"10.1053\/j.ackd.2015.12.004_bib7","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1056\/NEJM199006143222403","article-title":"Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease","volume":"322","author":"Pekkanen","year":"1990","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1053\/j.ackd.2015.12.004_bib8","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.1986.03380200061022","article-title":"Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)","volume":"256","author":"Stamler","year":"1986","journal-title":"JAMA"},{"issue":"9602","key":"10.1053\/j.ackd.2015.12.004_bib9","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","article-title":"Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths","volume":"370","author":"Lewington","year":"2007","journal-title":"Lancet"},{"issue":"2","key":"10.1053\/j.ackd.2015.12.004_bib10","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1681\/ASN.2004080656","article-title":"Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study","volume":"16","author":"Muntner","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"14","key":"10.1053\/j.ackd.2015.12.004_bib11","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1001\/jama.293.14.1737","article-title":"Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors","volume":"293","author":"Shlipak","year":"2005","journal-title":"JAMA"},{"issue":"12","key":"10.1053\/j.ackd.2015.12.004_bib12","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.2009121285","article-title":"Malnutrition-inflammation modifies the relationship of cholesterol with cardiovascular disease","volume":"21","author":"Contreras","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2015.12.004_bib13","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1681\/ASN.2006060674","article-title":"Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: effects of case mix and the malnutrition-inflammation-cachexia syndrome","volume":"18","author":"Kovesdy","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ackd.2015.12.004_bib14","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1681\/ASN.2012080870","article-title":"Association between LDL-C and risk of myocardial infarction in CKD","volume":"24","author":"Tonelli","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ackd.2015.12.004_bib15","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1053\/j.ajkd.2007.07.011","article-title":"GFR, body mass index, and low high-density lipoprotein concentration in adults with and without CKD","volume":"50","author":"Lo","year":"2007","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ackd.2015.12.004_bib16","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1053\/j.jrn.2009.04.002","article-title":"Relationship between adiposity and cardiovascular risk factors in prevalent hemodialysis patients","volume":"19","author":"Kaysen","year":"2009","journal-title":"J Ren Nutr"},{"issue":"5","key":"10.1053\/j.ackd.2015.12.004_bib17","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S0272-6386(00)70255-1","article-title":"Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation","volume":"35","author":"Deighan","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2015.12.004_bib18","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1038\/sj.ki.5001979","article-title":"Dyslipidemia in chronic kidney disease: causes and consequences","volume":"70","author":"Kaysen","year":"2006","journal-title":"Kidney Int"},{"issue":"8","key":"10.1053\/j.ackd.2015.12.004_bib19","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1194\/jlr.R600011-JLR200","article-title":"Thematic review series: patient-oriented research. Free fatty acid metabolism in human obesity","volume":"47","author":"Koutsari","year":"2006","journal-title":"J Lipid Res"},{"issue":"3","key":"10.1053\/j.ackd.2015.12.004_bib20","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.arcmed.2005.01.005","article-title":"Regulation of plasma triglycerides in insulin resistance and diabetes","volume":"36","author":"Ginsberg","year":"2005","journal-title":"Arch Med Res"},{"issue":"5","key":"10.1053\/j.ackd.2015.12.004_bib21","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.metabol.2004.12.014","article-title":"Intestinal assembly and secretion of highly dense\/lipid-poor apolipoprotein B48-containing lipoprotein particles in the fasting state: evidence for induction by insulin resistance and exogenous fatty acids","volume":"54","author":"Guo","year":"2005","journal-title":"Metabolism"},{"issue":"3","key":"10.1053\/j.ackd.2015.12.004_bib22","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1172\/JCI110812","article-title":"Plasma low density lipoprotein transport kinetics in noninsulin-dependent diabetes mellitus","volume":"71","author":"Kissebah","year":"1983","journal-title":"J Clin Invest"},{"key":"10.1053\/j.ackd.2015.12.004_bib23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2337\/diab.31.3.217","article-title":"Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in non-insulin-dependent diabetes mellitus","volume":"31","author":"Kissebah","year":"1982","journal-title":"Diabetes"},{"issue":"1","key":"10.1053\/j.ackd.2015.12.004_bib24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.atherosclerosis.2004.04.022","article-title":"Hepatic production of VLDL1 but not VLDL2 is related to insulin resistance in normoglycaemic middle-aged subjects","volume":"176","author":"Gill","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1053\/j.ackd.2015.12.004_bib25","first-page":"310","article-title":"Adipotoxicity and the insulin resistance syndrome","volume":"1","author":"Anderwald","year":"2004","journal-title":"Pediatr Endocrinol Rev"},{"issue":"18","key":"10.1053\/j.ackd.2015.12.004_bib26","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.1021\/bi9919504","article-title":"Role of the kidney in regulating the metabolism of HDL in rabbits: evidence that iodination alters the catabolism of apolipoprotein A-I by the kidney","volume":"39","author":"Braschi","year":"2000","journal-title":"Biochemistry"},{"issue":"10","key":"10.1053\/j.ackd.2015.12.004_bib27","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1161\/ATVBAHA.113.301597","article-title":"Chronic hyperinsulinemia does not increase the production rate of high-density lipoprotein apolipoprotein AI: evidence from a kinetic study in patients with insulinoma","volume":"33","author":"Duvillard","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1053\/j.ackd.2015.12.004_bib28","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1161\/01.HYP.17.3.386","article-title":"High density lipoprotein turnover in patients with hypertension","volume":"17","author":"Chen","year":"1991","journal-title":"Hypertension"},{"issue":"9","key":"10.1053\/j.ackd.2015.12.004_bib29","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/sj.ijo.0802070","article-title":"High-density lipoprotein apolipoprotein A-I kinetics in obese insulin resistant patients. An in\u00a0vivo stable isotope study","volume":"26","author":"Pont","year":"2002","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"9","key":"10.1053\/j.ackd.2015.12.004_bib30","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1161\/01.ATV.0000137975.14996.df","article-title":"Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes","volume":"24","author":"Welty","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1053\/j.ackd.2015.12.004_bib31","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/01.ASN.0000046962.43220.8A","article-title":"LCAT-dependent conversion of prebeta1-HDL into alpha-migrating HDL is severely delayed in hemodialysis patients","volume":"14","author":"Miida","year":"2003","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ackd.2015.12.004_bib32","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.metabol.2005.01.028","article-title":"Insulin resistance and postprandial triglyceride levels in primary renal disease","volume":"54","author":"Charlesworth","year":"2005","journal-title":"Metabolism"},{"issue":"3","key":"10.1053\/j.ackd.2015.12.004_bib33","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0009-9120(02)00300-4","article-title":"Related LDL and HDL subclass distribution in patients with end-stage renal diseases","volume":"35","author":"Alabakovska","year":"2002","journal-title":"Clin Biochem"},{"issue":"2","key":"10.1053\/j.ackd.2015.12.004_bib34","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2337\/diabetes.52.2.453","article-title":"Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance","volume":"52","author":"Garvey","year":"2003","journal-title":"Diabetes"},{"issue":"5","key":"10.1053\/j.ackd.2015.12.004_bib35","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1681\/ASN.2011070668","article-title":"Serum amyloid A in uremic HDL promotes inflammation","volume":"23","author":"Weichhart","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ackd.2015.12.004_bib36","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0021-9150(00)00568-2","article-title":"Acute-phase HDL in phospholipid transfer protein (PLTP)-mediated HDL conversion","volume":"155","author":"Pussinen","year":"2001","journal-title":"Atherosclerosis"},{"issue":"13","key":"10.1053\/j.ackd.2015.12.004_bib37","doi-asserted-by":"crossref","first-page":"9955","DOI":"10.1074\/jbc.M010265200","article-title":"Specific docking of apolipoprotein A-I at the cell surface requires a functional ABCA1 transporter","volume":"276","author":"Chambenoit","year":"2001","journal-title":"J Biol Chem"},{"issue":"44","key":"10.1053\/j.ackd.2015.12.004_bib38","doi-asserted-by":"crossref","first-page":"34508","DOI":"10.1074\/jbc.M006738200","article-title":"ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages","volume":"275","author":"Oram","year":"2000","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1053\/j.ackd.2015.12.004_bib39","doi-asserted-by":"crossref","first-page":"E144","DOI":"10.25011\/cim.v35i3.16590","article-title":"Increased oxidized-LDL levels and arylesterase activity\/HDL ratio in ESRD patients treated with hemodialysis","volume":"35","author":"Mahrooz","year":"2012","journal-title":"Clin Invest Med"},{"issue":"4","key":"10.1053\/j.ackd.2015.12.004_bib40","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/1520-7560(200007\/08)16:4<237::AID-DMRR127>3.0.CO;2-9","article-title":"Related reverse cholesterol transport in diabetes mellitus","volume":"16","author":"Quintao","year":"2000","journal-title":"Diabetes Metab Res Rev"},{"issue":"45","key":"10.1053\/j.ackd.2015.12.004_bib41","doi-asserted-by":"crossref","first-page":"26910","DOI":"10.1074\/jbc.270.45.26910","article-title":"Effects of the neutral lipid content of high density lipoprotein on apolipoprotein A-I structure and particle stability","volume":"270","author":"Sparks","year":"1995","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1053\/j.ackd.2015.12.004_bib42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00041433-200004000-00005","article-title":"Cubilin, a high-density lipoprotein receptor","volume":"11","author":"Moestrup","year":"2000","journal-title":"Curr Opin Lipidol"},{"issue":"2","key":"10.1053\/j.ackd.2015.12.004_bib43","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.atherosclerosis.2011.10.038","article-title":"Oxidized high-density lipoprotein as a risk factor for cardiovascular events in prevalent hemodialysis patients","volume":"220","author":"Honda","year":"2012","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1053\/j.ackd.2015.12.004_bib44","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/ndt\/gfp120","article-title":"Plasma phospholipid transfer protein, cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase in end-stage renal disease (ESRD)","volume":"24","author":"Pahl","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2015.12.004_bib45","doi-asserted-by":"crossref","first-page":"S227","DOI":"10.1046\/j.1523-1755.1999.07159.x","article-title":"Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients","volume":"71","author":"Oi","year":"1999","journal-title":"Kidney Int Suppl"},{"issue":"8","key":"10.1053\/j.ackd.2015.12.004_bib46","first-page":"CR439","article-title":"Effect of long-term hemodialysis on plasma lecithin: cholesterol acyltransferase activity and the amounts and compositions of HDL2 and HDL3 in hemodialysis-treated patients with chronic renal failure: a 9-year longitudinal study","volume":"10","author":"Mekki","year":"2004","journal-title":"Med Sci Monit"},{"issue":"1-2","key":"10.1053\/j.ackd.2015.12.004_bib47","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000351506","article-title":"Skew of plasma low- and high-density lipoprotein distributions to less dense subfractions in normotriglyceridemic chronic kidney disease patients on maintenance hemodialysis treatment","volume":"123","author":"Homma","year":"2013","journal-title":"Nephron Clin Pract"},{"issue":"1","key":"10.1053\/j.ackd.2015.12.004_bib48","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.atherosclerosis.2012.07.011","article-title":"Oxidized LDL to autoantibodies against oxLDL ratio\u2014the new biomarker associated with carotid atherosclerosis and cardiovascular complications in dialyzed patients","volume":"224","author":"Pawlak","year":"2012","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1053\/j.ackd.2015.12.004_bib49","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1093\/ndt\/12.12.2603","article-title":"Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients: a prospective study in 412 subjects","volume":"12","author":"Koch","year":"1997","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1053\/j.ackd.2015.12.004_bib50","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1177\/147323001103900445","article-title":"Correlation between ischaemia-modified albumin and intermediate-density lipoprotein in haemodialysis patients with end-stage renal disease","volume":"39","author":"Kotani","year":"2011","journal-title":"J Int Med Res"},{"issue":"7","key":"10.1053\/j.ackd.2015.12.004_bib51","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1681\/ASN.V971277","article-title":"Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients","volume":"9","author":"Shoji","year":"1998","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ackd.2015.12.004_bib52","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1681\/ASN.2014050450","article-title":"Mediation analysis of aortic stiffness and renal microvascular function","volume":"26","author":"Woodard","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ackd.2015.12.004_bib53","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00041433-200106000-00009","article-title":"Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism","volume":"12","author":"Shachter","year":"2001","journal-title":"Curr Opin Lipidol"},{"issue":"2","key":"10.1053\/j.ackd.2015.12.004_bib54","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0021-9150(96)05955-2","article-title":"Effect of the apolipoprotein C-II\/C-III1 ratio on the capacity of purified milk lipoprotein lipase to hydrolyse triglycerides in monolayer vesicles","volume":"127","author":"Lambert","year":"1996","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1053\/j.ackd.2015.12.004_bib55","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1523-1755.2002.00116.x","article-title":"Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiency","volume":"61","author":"Lee","year":"2002","journal-title":"Kidney Int"},{"issue":"7","key":"10.1053\/j.ackd.2015.12.004_bib56","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/sj.ki.5002449","article-title":"Hemodialysis reduces plasma apolipoprotein C-I concentration making VLDL a better substrate for lipoprotein lipase","volume":"72","author":"Dautin","year":"2007","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2015.12.004_bib57","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0021-9150(89)90075-0","article-title":"Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients. Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration","volume":"77","author":"Malmendier","year":"1989","journal-title":"Atherosclerosis"},{"issue":"5908","key":"10.1053\/j.ackd.2015.12.004_bib58","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1126\/science.1161524","article-title":"A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection","volume":"322","author":"Pollin","year":"2008","journal-title":"Science"},{"issue":"1","key":"10.1053\/j.ackd.2015.12.004_bib59","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Crosby","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.ackd.2015.12.004_bib60","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"J\u00f8rgensen","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1053\/j.ackd.2015.12.004_bib61","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.metabol.2010.04.017","article-title":"Apolipoprotein C-I genotype and serum levels of triglycerides, C-reactive protein and coronary heart disease","volume":"59","author":"Olsson","year":"2010","journal-title":"Metabolism"},{"key":"10.1053\/j.ackd.2015.12.004_bib62","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.bbrc.2010.12.105","article-title":"Isoforms of apolipoprotein C-I\u00a0associated with individuals with coronary artery disease","volume":"404","author":"Moore","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"10.1053\/j.ackd.2015.12.004_bib63","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1681\/ASN.V981474","article-title":"Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome","volume":"9","author":"De Sain-Van Der Velden","year":"1998","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ackd.2015.12.004_bib64","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/j.1523-1755.1998.00831.x","article-title":"Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis","volume":"53","author":"de Sain-van der Velden","year":"1998","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ackd.2015.12.004_bib65","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1523-1755.2001.00478.x","article-title":"Hypoalbuminemia and proteinuria contribute separately to reduced lipoprotein catabolism in the nephrotic syndrome","volume":"59","author":"Shearer","year":"2001","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ackd.2015.12.004_bib66","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S0272-6386(88)80110-0","article-title":"Hyperlipidemia in the nephrotic syndrome","volume":"12","author":"Kaysen","year":"1988","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2015.12.004_bib67","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1046\/j.1523-1755.1999.07105.x","article-title":"New insights into lipid metabolism in the nephrotic syndrome","volume":"71","author":"Kaysen","year":"1999","journal-title":"Kidney Int Suppl"},{"issue":"3","key":"10.1053\/j.ackd.2015.12.004_bib68","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/ndt\/gft439","article-title":"Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome","volume":"29","author":"Liu","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1053\/j.ackd.2015.12.004_bib69","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1046\/j.1523-1755.1998.00729.x","article-title":"Proportionate increase of fibrinogen and albumin synthesis in nephrotic patients: measurements with stable isotopes","volume":"53","author":"de Sain-van der Velden","year":"1998","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ackd.2015.12.004_bib70","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1046\/j.1523-1755.1999.00562.x","article-title":"Coordinate augmentation in expression of genes encoding transcription factors and liver secretory proteins in hypo-oncotic states","volume":"56","author":"Kang","year":"1999","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ackd.2015.12.004_bib71","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1681\/ASN.V1251017","article-title":"Transferrin synthesis is increased in nephrotic patients insufficiently to replace urinary losses","volume":"12","author":"Prinsen","year":"2001","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ackd.2015.12.004_bib72","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/ki.1995.153","article-title":"Non-iron mediated alteration in hepatic transferrin gene expression in the nephrotic rat","volume":"47","author":"Kaysen","year":"1995","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ackd.2015.12.004_bib73","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/ki.1994.180","article-title":"Albumin and transferrin synthesis are increased in H4 cells by serum from analbuminemic or nephrotic rats","volume":"45","author":"Sun","year":"1994","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ackd.2015.12.004_bib74","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1172\/JCI114750","article-title":"Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic rat","volume":"86","author":"Davies","year":"1990","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1053\/j.ackd.2015.12.004_bib75","first-page":"CD005425","article-title":"Lipid-lowering agents for nephrotic syndrome","author":"Kong","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1053\/j.ackd.2015.12.004_bib76","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/ki.1986.36","article-title":"Effect of dietary protein intake on albumin homeostasis in nephrotic patients","volume":"29","author":"Kaysen","year":"1986","journal-title":"Kidney Int"},{"issue":"8802","key":"10.1053\/j.ackd.2015.12.004_bib77","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/0140-6736(92)90731-H","article-title":"Effect of vegetarian soy\u00a0diet on hyperlipidaemia in nephrotic syndrome","volume":"339","author":"D'Amico","year":"1992","journal-title":"Lancet"},{"issue":"6","key":"10.1053\/j.ackd.2015.12.004_bib78","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1038\/ki.1987.151","article-title":"Albumin synthesis, albuminuria and hyperlipemia in nephrotic patients","volume":"31","author":"Kaysen","year":"1987","journal-title":"Kidney Int"},{"issue":"12","key":"10.1053\/j.ackd.2015.12.004_bib79","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1681\/ASN.2005070779","article-title":"Effect of pravastatin in people with diabetes and chronic kidney disease","volume":"16","author":"Tonelli","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.ackd.2015.12.004_bib80","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1161\/01.CIR.0000143892.84582.60","article-title":"Effect of pravastatin on cardiovascular events in people with chronic kidney disease","volume":"110","author":"Tonelli","year":"2004","journal-title":"Circulation"},{"issue":"2","key":"10.1053\/j.ackd.2015.12.004_bib81","doi-asserted-by":"crossref","first-page":"98","DOI":"10.7326\/0003-4819-138-2-200301210-00010","article-title":"Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency","volume":"138","author":"Tonelli","year":"2003","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1053\/j.ackd.2015.12.004_bib82","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1053\/j.ajkd.2009.03.022","article-title":"Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"54","author":"Colhoun","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"10.1053\/j.ackd.2015.12.004_bib83","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.jacc.2010.01.020","volume":"55","author":"Ridker","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1053\/j.ackd.2015.12.004_bib84","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1053\/j.ackd.2015.12.004_bib85","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstrom","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"9784","key":"10.1053\/j.ackd.2015.12.004_bib86","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"issue":"3","key":"10.1053\/j.ackd.2015.12.004_bib87","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1053\/j.ajkd.2008.05.027","article-title":"Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"52","author":"Rahman","year":"2008","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ackd.2015.12.004_bib88","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.atherosclerosis.2008.11.010","article-title":"Effect of simvastatin on kidney function loss in patients with coronary heart disease: findings from the Scandinavian Simvastatin Survival Study (4S)","volume":"205","author":"Huskey","year":"2009","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1053\/j.ackd.2015.12.004_bib89","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1161\/CIRCULATIONAHA.104.517565","article-title":"Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease","volume":"112","author":"Tonelli","year":"2005","journal-title":"Circulation"},{"issue":"3","key":"10.1053\/j.ackd.2015.12.004_bib90","first-page":"259","article-title":"KDIGO clinical practice guideline for lipid management in chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Inter Suppl"},{"issue":"5","key":"10.1053\/j.ackd.2015.12.004_bib91","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S0272-6386(04)01082-0","article-title":"Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease","volume":"44","author":"Tonelli","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ackd.2015.12.004_bib92","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1523-1755.2004.00862.x","article-title":"Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency","volume":"66","author":"Tonelli","year":"2004","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ackd.2015.12.004_bib93","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s00125-010-1951-1","article-title":"Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study","volume":"54","author":"Davis","year":"2011","journal-title":"Diabetologia"},{"issue":"8","key":"10.1053\/j.ackd.2015.12.004_bib94","doi-asserted-by":"crossref","first-page":"560","DOI":"10.7326\/0003-4819-156-8-201204170-00401","article-title":"New fibrate use and acute renal outcomes in elderly adults: a population-based study","volume":"156","author":"Zhao","year":"2012","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1053\/j.ackd.2015.12.004_bib95","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/1074248413514481","article-title":"The therapeutic role of niacin in dyslipidemia management","volume":"19","author":"Boden","year":"2014","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"2","key":"10.1053\/j.ackd.2015.12.004_bib96","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s11255-013-0559-z","article-title":"Benefits and harm of niacin and its analog for renal dialysis patients: a systematic review and meta- analysis","volume":"46","author":"He","year":"2014","journal-title":"Int Urol Nephrol"},{"issue":"3","key":"10.1053\/j.ackd.2015.12.004_bib97","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1681\/ASN.2013050545","article-title":"Provision of antioxidant therapy in hemodialysis (PATH): a randomized clinical trial","volume":"25","author":"Himmelfarb","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ackd.2015.12.004_bib98","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1681\/ASN.2013111178","article-title":"If oxidative stress is an appropriate and specific target, what reagent should we choose?","volume":"25","author":"Kaysen","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ackd.2015.12.004_bib99","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.1993.292","article-title":"The increased risk of coronary heart disease associated with nephrotic syndrome","volume":"44","author":"Ordonez","year":"1993","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ackd.2015.12.004_bib100","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1046\/j.1440-1797.2003.00143.x","article-title":"Atorvastatin in dyslipidaemia of the nephrotic syndrome","volume":"8","author":"Valdivielso","year":"2003","journal-title":"Nephrology (Carlton)"},{"issue":"5","key":"10.1053\/j.ackd.2015.12.004_bib101","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/ki.1993.358","article-title":"Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria","volume":"44","author":"Thomas","year":"1993","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ackd.2015.12.004_bib102","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s10157-014-0996-8","article-title":"Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study","volume":"19","author":"Muso","year":"2014","journal-title":"Clin Exp Nephrol"},{"issue":"2","key":"10.1053\/j.ackd.2015.12.004_bib103","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s10157-013-0930-5","article-title":"Beneficial effect of LDL-apheresis in refractory nephrotic syndrome","volume":"18","author":"Muso","year":"2014","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2015.12.004_bib104","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nm.3396","article-title":"Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome","volume":"20","author":"Clement","year":"2014","journal-title":"Nat Med"},{"issue":"2","key":"10.1053\/j.ackd.2015.12.004_bib105","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/nrneph.2013.267","article-title":"Nephrotic syndrome: negative feedback loop reveals novel potential therapy","volume":"10","author":"Kirk","year":"2014","journal-title":"Nat Rev Nephrol"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559515001664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559515001664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T22:49:52Z","timestamp":1656715792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559515001664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":105,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S1548559515001664"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2015.12.004","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Hyperlipidemia Changes With Level of Kidney Function\u2014Rationale","name":"articletitle","label":"Article Title"},{"value":"Advances in Chronic Kidney Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ackd.2015.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}